As sales of Incyte Corp.'s approved JAK inhibitor Jakafi (ruxolitinib) begin to pick up steam, a competing myelofibrosis candidate from Sanofi SA moved a step closer to market. Read More
PTC Therapeutics Inc. made last week a biotech trifecta for initial public offerings (IPO), filing an S-1 with the SEC seeking to raise up to $85 million. Earlier, gene therapy firm bluebird bio Inc. and Esperion Therapeutics Inc., a company working on a drug to lower LDL-cholesterol, joined the IPO queue. Read More
Through the indirect targeting of toll-like receptors via their co-receptor, researchers have boosted the immune response to infection, and helped animals with experimentally induced sepsis fight off the bacteria that set off the septic response. Read More
Taking an inventive route to drug development, Oncos Therapeutics Ltd. has its roots in a type of compassionate use program that was started in 2007 at the international comprehensive cancer center, Docrates, in Helsinki, Finland. Read More
• XenoPort Inc., of Santa Clara, Calif., said shipments of Horizant (gabapentin enacarbil) extended-release tablets to its U.S. distributor have commenced and, depending on individual pharmacy ordering patterns, the product is expected to be generally available to patients in the first week of June. Read More
• Insero Health Inc., of Miami, reported top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy. Read More
• UCB SA, of Brussels, Belgium, said data from a double-blind, placebo-controlled study found that Neupro (rotigotine transdermal system) reduced total nocturnal systolic blood pressure (NSBP) elevations associated with periodic limb movements during sleep (PLMS) and total PLMS in patients with idiopathic moderate to severe restless legs syndrome (RLS)/Willis-Ekbom disease. Read More
• Mylan Inc., of Pittsburgh, said its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. Mylan Pharmaceuticals received final approval from the FDA for its abbreviated new drug application for this product, which is the generic version of Tricor (fenofibrate, AbbVie). Read More
Inhibitors of the enzyme poly(ADP-ribose) polymerase (PARP) selectively kill cells with BRCA mutations, and researchers at the University of Michigan have discovered one reason that they do so. Read More
